Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.58 |
| ▸ | HTR2A | P28223 | 6/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | APLNR | P35414 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640743 | 0.87 | APLNR (0.57) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL680457 | 0.86 | APLNR (0.76) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL29485595 | 0.86 | APLNR (0.76) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| Hydrochloric Acid SCHEMBL30718133 | 0.84 | APLNR (0.73) | SLC6A4HTR2AKCNH2APLNRSLC6A2 | |
| SCHEMBL24075695 | 0.82 | APLNR (0.50) | APLNRMTNR1AMTNR1BTSHR | |
| SCHEMBL12844149 | 0.79 | APLNR (0.47) | APLNRMTNR1AMTNR1BTSHR | |
| SCHEMBL9809277 | 0.79 | APLNR (0.47) | APLNRGAAMTNR1AMTNR1B | |
| SCHEMBL11835176 | 0.79 | APLNR (0.44) | SLC6A4HTR2AKCNH2APLNRTP53 | |
| SCHEMBL14183054 | 0.77 | CA12 (0.48) | APLNRGAAMTNR1AMTNR1BTSHR | |
| SCHEMBL12775731 | 0.77 | APLNR (0.45) | APLNRTP53GAAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | SLC6A4 1228/4885HTR2A 1464/4885KCNH2 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.